Nora Yang, Ph.D., Chief Scientific Officer

Oct. 13 | 4:15pm | BlueRock Therapeutics Ballroom

Montpellier, France


In-person Presentation

Sensorion is a clinical-stage biotech company which specializes in the development of novel therapies to restore, treat, and prevent within the field of hearing loss disorders. Its clinical-stage portfolio includes one Phase II product: SENS-401 for sudden sensorineural hearing loss. Sensorion has built a unique R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases enabling it to select the best targets and modalities for drug candidates. The company is also working on the identification of biomarkers to improve diagnosis of these underserved illnesses. Sensorion has launched three gene therapy programs, currently at preclinical stage, aimed at correcting hereditary monogenic forms of deafness including deafness caused by a mutation of the gene encoding for Otoferlin, hearing loss related to gene target GJB2, as well as Usher Syndrome Type 1 to potentially address important hearing loss segments in adults and children.

By using this website you agree to accept our Privacy Policy and Terms & Conditions